Rite Aid Corp. (NYSE: RAD) is expected to report its fiscal second-quarter results on Thursday before the markets open. The analysts’ consensus estimates call for EPS of $0.04 and $7.56 billion in revenue.
The company is one of the nation’s leading drugstore chains, with nearly 4,600 stores in 31 states and the District of Columbia. Many on Wall Street see the company very favorably positioned in health care, given its geographic overlap with Medicaid expansion, as well as its push into clinics.
Shares were changing hands at the end of the week at $8.61. The consensus analyst price target is $10.05, and the stock has a 52-week trading range of $4.42 to $9.47.